SCHEMBL6487649

SCHEMBL6487649

Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1cccc(OCC(O)CN(C)CCCN(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.59
SMO Q99835 2/20 0.58
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
BRAF P15056 2/20 0.55
RAF1 P04049 1/20 0.55
TP53 P04637 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
ALOX15 P16050 1/20 0.55
MAPK11 Q15759 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
CSF1R P07333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6570477 0.91 MAPK14 (0.66) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6477223 0.85 MAPK14 (0.65) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL27481605 0.81 MAPK14 (0.53) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6487696 0.80 MAPK14 (0.59) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6485478 0.80 MAPK14 (0.71) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6484472 0.79 MAPK14 (0.58) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6477135 0.79 MAPK14 (0.71) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6528122 0.78 MAPK14 (0.49) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6477189 0.77 MAPK14 (0.67) MAPK14SMOKDM4EALDH1A1MAPT
SCHEMBL6782690 0.77 MAPK14 (0.85) MAPK14SMOKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956037-B2 Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRAZENECA AB (SE) 2005-10-18 US disclosed
US-20030212068-A1 Benzamide derivatives for the treatment of diseases mediated by cytokines ASTRAZENECA AB 2003-11-13 US disclosed
US-6579872-B1 Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide ASTRAZENECA AB (SE) 2003-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212068-A1 Benzamide derivatives for the treatment of diseases mediated by cytokines IL2, IL6, IL6ST MAPK14 2054/4885SMO 4147/4885KDM4E 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.